cas 4472-44-0|| where to buy 2-Chloro-4,6-dimethylpyrimidine

Product Name:2-Chloro-4,6-dimethylpyrimidine

IUPAC Name:2-chloro-4,6-dimethylpyrimidine

Packing Unit	Available Stock	Price($)
CM121158-100g	in stock	ȎƄŢ
CM121158-500g	in stock	ƞĽư

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 4472-44-0 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:4472-44-0; Molecular Formula:C6H7ClN2; Melting Point:-; Smiles Code:CC1=CC(C)=NC(Cl)=N1; Density:

: Catalog Number:CM121158; Molecular Weight:142.59; Boiling Point:216°C at 760 mmHg; MDL No:MFCD00023199; Storage:Keep in dark place, inert atmosphere, store at 2-8°C.

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Seltorexant; Johnson & Johnson pivotal study of Seltorexant shows statistically significant and clinically meaningful improvement in depressive symptoms and sleep disturbance outcomes. Seltorexant meets all primary and secondary endpoints in the pivotal Phase 3 MDD3001 clinical trial of adult and elderly patients with major depressive disorder (MDD) with insomnia symptoms.
Orexin signaling pathways are found to be associated with depression and anxiety. Orexin neurons receive and transmit signals throughout the central nervous system (CNS) that are modulated by their specific receptors (OX1R, OX2R). Seltorexant is an investigational first-in-class selective antagonist of ORX2 receptor. It is developed as an adjunctive therapy for MDD and for the treatment of insomnia disorder.